Team Startupcity

·  Arintra secures $21M Series A funding led by Peak XV Partners with multiple global investors.

·  GenAI-native platform automates medical coding, CDI, and denial prevention for healthcare providers.

·  Plans to expand in the U.S., accelerate product development, and open new Bay Area HQ.

Arintra, a GenAI-native autonomous medical coding platform, has raised $21 million in a Series A round led by Peak XV Partners, with further investment from Endeavor Health Ventures, Y Combinator, Counterpart Ventures, Spider Capital, Ten13, and other strategic investors.

The funding will be used to drive Arintra's growth in U.S. health systems and physician groups, advance product development, expand its team, and open a new headquarters in the Bay Area.

Also Read- Olee.space Secures $3Million Seed Funding

Established in 2020 by Preeti Bhargava and Nitesh Shroff, Arintra streamlines the process of converting clinical documentation into precise insurance codes, also integrating clinical documentation improvement (CDI) and denial prevention within a single platform. With seamless integration into EHR platforms such as Epic and Athena, it can function effortlessly within existing workflows.

The company's enterprise SaaS solution seeks to assist healthcare providers with complete, compliant reimbursement, reduced cost of operations, enhanced claim accuracy, and accelerated cash flow.

"Reimbursement in healthcare is broken at its core," stated Shroff, CEO of Arintra. "Payers are acting swiftly, placing more burden on providers, yet autonomous coding has been behind. Arintra allows providers to achieve compliant revenue at scale while taking pressure off frontline teams.

Focusing on big healthcare systems, hospitals, and medical groups, Arintra provides quantifiable ROI via its revenue assurance-driven methodology.